Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.